Japan· JP-4291035F1023
シロリムス
A sirolimus product containing シロリムス, registered in Japan by ノーベルファーマ, on the national reimbursement list. The same ATC class is registered in 6 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Sirolimus is registered in 6 of 19 countries.
Countries holding a registration under ATC L01EG04 (sirolimus), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 4 of them publish a price we can compare per daily dose
Sirolimus · ATC L01EG04
6 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Japan
- Norwayprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- シロリムス
- Manufacturer
- ノーベルファーマ
- Country
- Japan (JP)
- ATC code
- L01EG04
- ATC class
- Sirolimus
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
737 interactions on record for sirolimus.
Graded by severity as the source publishes them — 162 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sirolimus · interactions on record
737 records
- 162 severe
- 441 moderate
- 8 minor
- 126 info
Most severe, free to view
- ClotrimazoleA01AB18severe
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EG04
Sirolimus, as other registers publish it.
- DenmarkHyftorPlusultra Pharma GmbH
- FinlandHyftorPlusultra Pharma GmbH
- CzechiaHYFTORPlusultra pharma GmbH, Düsseldorf
- BelgiumHyftor 2 mg/gPlusultra Pharma
- NorwaySirolimus apotheke roter ochsenApotheke Roter Ochsen
- NorwaySirolimus apotheke roter ochsenApotheke Roter Ochsen
- Japanシロリムスノーベルファーマ
- Japanシロリムスノーベルファーマ
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f16dbb0e-d5a2-4a4e-b7f6-0e52676c4c13 GET /v1/drugs/f16dbb0e-d5a2-4a4e-b7f6-0e52676c4c13?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291035F1023",
"category": "内用薬",
"price_yen": 1308.8,
"generic_name": "シロリムス",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about sirolimus.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.